Aileen L. Pangan

8.3k total citations · 8 hit papers
94 papers, 5.4k citations indexed

About

Aileen L. Pangan is a scholar working on Rheumatology, Hematology and Immunology. According to data from OpenAlex, Aileen L. Pangan has authored 94 papers receiving a total of 5.4k indexed citations (citations by other indexed papers that have themselves been cited), including 73 papers in Rheumatology, 38 papers in Hematology and 33 papers in Immunology. Recurrent topics in Aileen L. Pangan's work include Rheumatoid Arthritis Research and Therapies (53 papers), Spondyloarthritis Studies and Treatments (40 papers) and Autoimmune and Inflammatory Disorders Research (38 papers). Aileen L. Pangan is often cited by papers focused on Rheumatoid Arthritis Research and Therapies (53 papers), Spondyloarthritis Studies and Treatments (40 papers) and Autoimmune and Inflammatory Disorders Research (38 papers). Aileen L. Pangan collaborates with scholars based in United States, Germany and Canada. Aileen L. Pangan's co-authors include Joachim Sieper, Désirée van der Heijde, Philip J. Mease, Yijie Zhou, Walter P. Maksymowych, Filip Van den Bosch, Heidi S. Camp, Mohamed I. A. Othman, J. Anderson and Mark C. Genovese and has published in prestigious journals such as New England Journal of Medicine, The Lancet and Gastroenterology.

In The Last Decade

Aileen L. Pangan

93 papers receiving 5.3k citations

Hit Papers

Once-daily upadacitinib v... 2018 2026 2020 2023 2021 2018 2019 2018 2019 100 200 300
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Once-daily upadacitinib versus placebo in adolescents and adults with moderate-to-severe atopic dermatitis (Measure Up 1 and Measure Up 2): results from two replicate double-blind, randomised controlled phase 3 trials
    2021 350 citations Emma Guttman‐Yassky, Henrique D. Teixeira et al. The Lancet profile →
  2. Safety and efficacy of upadacitinib in patients with active rheumatoid arthritis refractory to biologic disease-modifying anti-rheumatic drugs (SELECT-BEYOND): a double-blind, randomised controlled phase 3 trial
    2018 331 citations Ying Zhang, Yijie Zhou et al. The Lancet profile →
  3. Upadacitinib Versus Placebo or Adalimumab in Patients With Rheumatoid Arthritis and an Inadequate Response to Methotrexate: Results of a Phase III, Double‐Blind, Randomized Controlled Trial
    2019 329 citations Aileen L. Pangan, In‐Ho Song et al. Arthritis & Rheumatology profile →
  4. Safety and efficacy of upadacitinib in patients with rheumatoid arthritis and inadequate response to conventional synthetic disease-modifying anti-rheumatic drugs (SELECT-NEXT): a randomised, double-blind, placebo-controlled phase 3 trial
    2018 294 citations Gerd R Burmester, Joel M. Kremer et al. The Lancet profile →
  5. Upadacitinib as monotherapy in patients with active rheumatoid arthritis and inadequate response to methotrexate (SELECT-MONOTHERAPY): a randomised, placebo-controlled, double-blind phase 3 study
    2019 260 citations Josef S Smolen, Aileen L. Pangan et al. The Lancet profile →
  6. Upadacitinib in adults with moderate to severe atopic dermatitis: 16-week results from a randomized, placebo-controlled trial
    2019 255 citations Emma Guttman‐Yassky, Diamant Thaçi et al. Journal of Allergy and Clinical Immunology profile →
  7. Trial of Upadacitinib and Adalimumab for Psoriatic Arthritis
    2021 182 citations Iain B. McInnes, J. Anderson et al. profile →
  8. Trial of Upadacitinib or Abatacept in Rheumatoid Arthritis
    2020 181 citations Aileen L. Pangan, Maureen Rischmueller et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Aileen L. Pangan United States 35 4.0k 2.0k 2.0k 767 722 94 5.4k
Sudha Visvanathan United States 35 3.5k 0.9× 2.5k 1.2× 1.7k 0.8× 244 0.3× 517 0.7× 71 5.4k
Carol A. Connell United States 17 2.6k 0.7× 866 0.4× 1.3k 0.6× 788 1.0× 262 0.4× 39 3.8k
Luminita Pricop United States 30 2.7k 0.7× 3.5k 1.8× 1.6k 0.8× 231 0.3× 531 0.7× 115 4.7k
Hanno B. Richards United States 35 3.4k 0.9× 3.5k 1.7× 1.5k 0.7× 393 0.5× 411 0.6× 58 5.0k
G Spencer-Green United States 19 2.8k 0.7× 908 0.5× 1.1k 0.5× 375 0.5× 279 0.4× 40 4.1k
Terence Rooney United States 28 2.9k 0.7× 806 0.4× 1.4k 0.7× 932 1.2× 197 0.3× 53 3.9k
Daniel Burge United States 14 2.6k 0.7× 1.6k 0.8× 1.5k 0.8× 266 0.3× 355 0.5× 23 3.9k
Arthur F. Kavanaugh United States 17 2.8k 0.7× 1.0k 0.5× 1.2k 0.6× 313 0.4× 56 0.1× 27 3.7k
Edward M Vital United Kingdom 34 2.6k 0.6× 2.0k 1.0× 333 0.2× 509 0.7× 116 0.2× 147 3.9k
Barbara Finck United States 8 2.7k 0.7× 1.3k 0.7× 1.5k 0.8× 246 0.3× 184 0.3× 17 3.6k

Countries citing papers authored by Aileen L. Pangan

Since Specialization
Citations

This map shows the geographic impact of Aileen L. Pangan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Aileen L. Pangan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Aileen L. Pangan more than expected).

Fields of papers citing papers by Aileen L. Pangan

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Aileen L. Pangan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Aileen L. Pangan. The network helps show where Aileen L. Pangan may publish in the future.

Co-authorship network of co-authors of Aileen L. Pangan

This figure shows the co-authorship network connecting the top 25 collaborators of Aileen L. Pangan. A scholar is included among the top collaborators of Aileen L. Pangan based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Aileen L. Pangan. Aileen L. Pangan is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Heijde, Désirée van der, Xenofon Baraliakos, Joachim Sieper, et al.. (2022). Efficacy and safety of upadacitinib for active ankylosing spondylitis refractory to biological therapy: a double-blind, randomised, placebo-controlled phase 3 trial. Annals of the Rheumatic Diseases. 81(11). 1515–1523. 79 indexed citations
2.
Panaccione, Remo, Silvio Danese, Aileen L. Pangan, et al.. (2022). A145 EFFICACY AND SAFETY OF UPADACITINIB MAINTENANCE THERAPY IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: RESULTS FROM A RANDOMIZED PHASE 3 STUDY. Journal of the Canadian Association of Gastroenterology. 5(Supplement_1). 18–19. 3 indexed citations
3.
McInnes, Iain B., Koji Kato, Marina Magrey, et al.. (2021). AB0523 LONG-TERM SAFETY AND EFFECTIVENESS OF UPADACITINIB IN PATIENTS WITH PSORIATIC ARTHRITIS: RESULTS AT 56 WEEKS FROM THE SELECT-PsA 1 STUDY. Annals of the Rheumatic Diseases. 80. 1288–1289. 4 indexed citations
4.
Vermeire, Séverine, Silvio Danese, Wen Zhou, et al.. (2021). S771 Efficacy and Safety of Upadacitinib as Induction Therapy in Patients With Moderately to Severely Active Ulcerative Colitis: Results From Phase 3 U-ACCOMPLISH Study. The American Journal of Gastroenterology. 116(1). S357–S357. 1 indexed citations
5.
Danese, Silvio, Séverine Vermeire, Wen Zhou, et al.. (2021). OP24 Efficacy and safety of upadacitinib induction therapy in patients with Moderately to Severely Active Ulcerative Colitis: Results from the phase 3 U-ACHIEVE study. Journal of Crohn s and Colitis. 15(Supplement_1). S022–S024. 15 indexed citations
6.
Coates, Laura C., Sonya Abraham, William Tillett, et al.. (2020). Performance and Predictors of Minimal Disease Activity Response in Patients With Peripheral Spondyloarthritis Treated With Adalimumab. Arthritis Care & Research. 74(2). 259–267. 4 indexed citations
7.
8.
Guttman‐Yassky, Emma, Diamant Thaçi, Aileen L. Pangan, et al.. (2019). Upadacitinib in adults with moderate to severe atopic dermatitis: 16-week results from a randomized, placebo-controlled trial. Journal of Allergy and Clinical Immunology. 145(3). 877–884. 255 indexed citations breakdown →
9.
Heijde, Désirée van der, Aileen L. Pangan, Atul Deodhar, et al.. (2019). Efficacy and safety of upadacitinib in patients with active ankylosing spondylitis (SELECT-AXIS 1): a multicentre, randomised, double-blind, placebo-controlled, phase 2/3 trial. The Lancet. 394(10214). 2108–2117. 242 indexed citations
10.
Smolen, Josef S, Aileen L. Pangan, Paul Emery, et al.. (2019). Upadacitinib as monotherapy in patients with active rheumatoid arthritis and inadequate response to methotrexate (SELECT-MONOTHERAPY): a randomised, placebo-controlled, double-blind phase 3 study. The Lancet. 393(10188). 2303–2311. 260 indexed citations breakdown →
11.
12.
Burmester, Gerd R, Joel M. Kremer, Filip Van den Bosch, et al.. (2018). Safety and efficacy of upadacitinib in patients with rheumatoid arthritis and inadequate response to conventional synthetic disease-modifying anti-rheumatic drugs (SELECT-NEXT): a randomised, double-blind, placebo-controlled phase 3 trial. The Lancet. 391(10139). 2503–2512. 294 indexed citations breakdown →
13.
14.
Bosch, Filip Van den, Philip J. Mease, Joachim Sieper, et al.. (2018). Long-term efficacy and predictors of remission following adalimumab treatment in peripheral spondyloarthritis: 3-year results from ABILITY-2. RMD Open. 4(1). e000566–e000566. 5 indexed citations
15.
Mease, Philip J., et al.. (2017). Performance of 3 Enthesitis Indices in Patients with Peripheral Spondyloarthritis During Treatment with Adalimumab. The Journal of Rheumatology. 44(5). 599–608. 36 indexed citations
16.
Kobayashi, S, Masayoshi Harigai, Neelufar Mozaffarian, et al.. (2012). A multicenter, open-label, efficacy, pharmacokinetic, and safety study of adalimumab in Japanese patients with ankylosing spondylitis. Modern Rheumatology. 22(4). 589–597. 12 indexed citations
17.
Keystone, Edward, Arthur Kavanaugh, Michael E. Weinblatt, Kaushik Patra, & Aileen L. Pangan. (2011). Clinical Consequences of Delayed Addition of Adalimumab to Methotrexate Therapy Over 5 Years in Patients with Rheumatoid Arthritis. The Journal of Rheumatology. 38(5). 855–862. 24 indexed citations
18.
Gooch, Katherine, David Feeny, H. Küpper, et al.. (2011). Is the Health Utilities Index 3 valid for patients with ankylosing spondylitis?. Value in Health. 14(1). 160–165. 4 indexed citations
19.
Burmester, Gerd R, Philip J. Mease, Ben A. C. Dijkmans, et al.. (2009). Adalimumab safety and mortality rates from global clinical trials of six immune-mediated inflammatory diseases. Annals of the Rheumatic Diseases. 68(12). 1863–1869. 159 indexed citations
20.
Heijde, Désirée van der, Aileen L. Pangan, Michael Schiff, et al.. (2007). Adalimumab effectively reduces the signs and symptoms of active ankylosing spondylitis in patients with total spinal ankylosis. Annals of the Rheumatic Diseases. 67(9). 1218–1221. 47 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Sudha Visvanathan Breakdown of academic impact, for papers by Carol A. Connell Breakdown of academic impact, for papers by Luminita Pricop Breakdown of academic impact, for papers by Hanno B. Richards Breakdown of academic impact, for papers by G Spencer-Green Breakdown of academic impact, for papers by Terence Rooney Breakdown of academic impact, for papers by Daniel Burge Breakdown of academic impact, for papers by Arthur F. Kavanaugh Breakdown of academic impact, for papers by Edward M Vital Breakdown of academic impact, for papers by Barbara Finck
Rankless by CCL
2026